Xeris Pharmaceuticals, Inc., the maker of Gvoke HypoPen® (glucagon injection), is dedicated to unlocking the potential of glucagon. We believe that our technology can have a profound impact on the lives of patients and their families. That’s why we are proud to be the first to develop liquid glucagon, but that’s just the beginning. We’re also studying how our formulation technology can impact patients with other conditions. We have a persistent drive to pursue solutions that have the potential to change lives. Get to know us and see how our technology is unlocking the potential of today’s medicines at www.xerispharma.com.